UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New vaccine plus immunotherapy shows promise against HPV-Linked head and neck cancer
Disease control Recruiting nowThis trial tests whether adding a vaccine called BNT113 to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer linked to HPV16. About 350 participants will receive either the combination or the standard single d…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC